KRAS and colorectal carcinoma: For instance, a study examining 408 CRC tumors reported that 33.1% (n = 135) of tumors exhibited KRAS exon 2 mutations, while NRAS mutations in exons 2 and 3 were identified in 2.4% of cases (n = 10) [39].